Preview

Systemic Hypertension

Advanced search

Β-blockers: the lack of taskimplementation or the unwillingness of doctors in the russian federation to optimize the treatment?

Abstract

The purpose of the study. The achievedheart rate of 50-60 beats per minute in patients after acute myocardial infarction, and up to50-70 beats per minute for patients with stable angina is considered effective. Assuming that in Russia low doses of β-blockers are often used, thequestion was raised: «How common tachycardia can bein patients with coronary heart disease (CHD) and chronic heart failure (CHF), and whether there are strategic approaches to achieving the targets in heart rate in these patients in real clinical practice and are β-blockers often used in patients for whom this group of drugs is the basic one?»Materials and Methods. Work carried out in the framework of the Russian epidemiological study of a representative sample of the European partof the Russian Federation. All patients with CHF and coronary artery disease were divided into two subgroups: heart rate reducers not receiving medicines and receiving at least one heart rate reducing drug (a β-blocker, calcium channel 1 and 3rd type (AK) blockers, glycosides).Results and discussion. In a representative sample of the program in healthy individuals (without clinical manifestations of coronary arterydisease) tachycardia was diagnosed in 7,1% of cases. Almost all respondents without CHD (87,3%) had normal heart rate from 61 to 80 beats per minute. Number of respondents without CHD with heart rate of 70 to 79 bpm. per min. (54,1%) turned out to be significantly less than that of patients with rhythm in any form of coronary artery disease (p<0,001).In a population of patients with CHF a clinical symptom of tachycardia was established in 73,5% of patients.Analysis of the prescribed β-blockers therapy in patients with CHF showed that in 54% of cases the use of beta-blockers did not result in effectivecontrol of the rhythm in patients with CHF. β-Blockers recommended for the treatment of CHF were used only 36,2% of patients.Conclusions. Early intravenous β-blockers (drug Betalok) use before percutaneous coronary intervention reduces infarct size and increases leftventricular ejection fraction in patients with myocardial infarction of ST segment elevation. Answering the question posed in the title, you can say: doctors are not ready to take an active position in prescribing and achievingthe target doses of β-blockers. This situation immediately generates the lack of task implementation in terms of optimization of therapy and reduces the risk of cardiovascular mortality in coronary artery disease and heart failure.

About the Authors

I. V. Fomin
ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России
Russian Federation


D. S. Polyakov
ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России
Russian Federation


References

1. Kristal-Boneh E, Silber H, Harari G, Froom P. The association of resting heart rate with cardiovascular, cancer and all - cause mortality. Eight year follow - up of 3527 male Isreali employees (the CORDIS study). Eur Heart J 2000; 21: 116-24.

2. Seccareccia F, Pannozzo F, Dima F et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001; 91: 1258-63.

3. Jouven X, Empana J.P, Escolano S et al. Relation of heart rate at rest and long - term (20 years) death rate in initially healthy middle - aged men. Am J Cardiol 2009; 103: 279-83.

4. Reunanen A, Karjalainen J, Ristola P et al. Heart rate and mortality. J Intern Med 2000; 247: 231-9.

5. Nauman J, Janszky I, Vatten L.J, Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011; 306: 2579-87.

6. Fox K, Ford I, Steg P.G et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-21.

7. Heidland U.E, Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.

8. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.

9. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.

10. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012; 33: 1787-847.

11. Ferrari R. Prognostic benefits of heart rate reduction in cardiovascular disease. Eur Heart J 2003; 5 (Suppl. G): G10-G4.

12. Kannel W.B. Heart rate and cardiovascular mortality. The Framingham Study. Am Heart J 1987; 113: 1489-94.

13. ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. EurIbanez B et al. Circulation 2013; 128: 1495-503.Heart J 2013; 34: 2949-3003.

14. Swedberg K, Komajda M, Bohm M et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo - controlled trial. Lancet 2010; 376: 875-85.

15. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Этиологические причины формирования ХСН в Европейской части Российской Федерации (госпитальный этап). Сердечная недостаточность. 2011; 6: 460-7.

16. Мареев В.Ю., Беленков Ю.Н., Агеев Ф.Т. и др. Первые результаты Российского эпидемиологического исследования по ХСН (ЭПОХА-ХСН). Сердечная недостаточность. 2003;4 (1): 17-8.

17. Bangalore S, Steg G, Deedwania P et al. b-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery. JAMA 2012; 308 (13): 1340-9.

18. Wikstrand J, Hjalmarson A, Waagstein F et al. Dose of Metoprolol CR/XL and Clinical Outcomes in Patients With Heart Failure. J Am Coll Cardiol 2002; 40: 491-8.

19. Gottlieb S, Fisher M.L, Kjekshus J et al. Tolerability of beta - blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002; 105: 1182-8.

20. Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta - analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665; doi: 10.1136/bmj.b1665

21. Larose E, Rodes-Cabau J, Pibarot P et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance.J Am Coll Cardiol 2010; 55: 2459-69.

22. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.

23. Chen Z.M, Pan H.C, Chen Y.P et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomized placebo - controlled trial. Lancet 2005; 366: 1622-32.

24. Roberts R, Rogers W.J, Meuller H.S et al. Immediate versus deferred beta - blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422-37.

25. Bates E.R. Role of Intravenous b-Blockers in the Treatment of ST-Elevation Myocardial Infarction: Of Mice (Dogs, Pigs) and Men. Circulation 2007; 115: 2904-6.

26. O’Gara P.T, Kushner F.G, Ascheim D.D et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-e425.

27. Steg P.G, James S.K, Atar D et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.

28. Ibanez B, Macaya C, Sanchez-Brunete V et al. Effect of Early Metoprolol on Infarct Size in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary PCI: The METOCARD-CNIC Trial. Circulation 2013; 128: 1495-503.


Review

For citations:


Fomin I.V., Polyakov D.S. Β-blockers: the lack of taskimplementation or the unwillingness of doctors in the russian federation to optimize the treatment? Systemic Hypertension. 2014;11(1):56-63. (In Russ.)

Views: 114


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)